Using the industry peer median P/E Multiples multiple (trailing + forward), Veracyte, Inc. (VCYT) has a fair value of $70.41 based on 1 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| Veracyte, Inc.VCYT | 3,284 | 49.7x | 22.8x |
| Kiniksa Pharmaceuticals, Ltd. | 4,348 | 78.1x | 42.8x |
| Industry Median | 78.1x | 42.8x | |
| (*) Profit after tax | 66 | 144 | |
| Equity Value | 5,184 | 6,162 | |
| (/) Outstanding shares | 81 | 81 | |
| Fair Price | $64 | $76 | |
Using the industry peer median EV/EBITDA multiple (trailing + forward), Veracyte, Inc. (VCYT) has a fair value of $93.24 based on 3 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| Veracyte, Inc.VCYT | 3,284 | 33.0x | 29.2x |
| Apellis Pharmaceuticals, Inc. | 5,253 | 75.3x | 87.2x |
| Amicus Therapeutics, Inc. | 4,550 | 89.6x | 75.4x |
| Kiniksa Pharmaceuticals, Ltd. | 4,348 | 46.4x | 33.4x |
| Industry Median | 75.3x | 75.4x | |
| (*) EBITDA | 90 | 101 | |
| = Enterprise Value | 6,749 | 7,630 | |
| (-) Net Debt | -323 | -323 | |
| Equity Value | 7,072 | 7,953 | |
| (/) Outstanding shares | 81 | 81 | |
| Fair Price | $88 | $99 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), Veracyte, Inc. (VCYT) has a fair value of $42.97 based on 9 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Veracyte, Inc.VCYT | 3,284 | 5.7x | 5.1x |
| Scholar Rock Holding Corporation | 5,336 | 159.7x | — |
| Apellis Pharmaceuticals, Inc. | 5,253 | 5.3x | 6.1x |
| Legend Biotech Corporation | 5,201 | 4.6x | 3.3x |
| Amicus Therapeutics, Inc. | 4,550 | 7.6x | 6.4x |
| Kiniksa Pharmaceuticals, Ltd. | 4,348 | 6.2x | 4.5x |
| Tarsus Pharmaceuticals, Inc. | 2,722 | 5.8x | 3.8x |
| IDEAYA Biosciences, Inc. | 2,488 | 11.0x | 69.2x |
| Adaptive Biotechnologies Corporation | 2,210 | 8.7x | 8.5x |
| Zai Lab Limited | 2,188 | 3.8x | 3.5x |
| Industry Median | 6.2x | 5.3x | |
| (*) Revenue | 517 | 584 | |
| = Enterprise Value | 3,200 | 3,079 | |
| (-) Net Debt | -323 | -323 | |
| Equity Value | 3,523 | 3,402 | |
| (/) Outstanding shares | 81 | 81 | |
| Fair Price | $44 | $42 | |
Using the PEG framework with analyst consensus forward EPS growth of 23.3%, the company has a fair value of $41.71 based on NTM EPS (FY2026) of $1.79. The current PEG ratio is 0.98.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
PEG is most informative for high-growth companies — the PEG sweet spot.
| EPS Growth RateForward | 23.3% |
| Adjusted Growth (clamped 8–25%) | 23.3% |
| Fair P/E | 23.3x |
| NTM EPS (FY2026) | $1.79 |
| Fair Value | $41.71 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $0.82 | — | — |
| FY2026E | $1.79 | +118.0% | 8 |
| FY2027E | $1.85 | +3.4% | 9 |
| FY2028E | $1.96 | +6.2% | 9 |
| FY2029E | $2.17 | +10.6% | 4 |
| FY2030E | $2.34 | +7.8% | 4 |
5Y Forward EPS CAGR: 23.3%
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-75.6M | $-1.11 | — |
| FY2022 | $-36.6M | $-0.51 | — |
| FY2023 | $-74.4M | $-1.02 | — |
| FY2024 | $24.1M | $0.31 | — |
| FY2025 | $66.4M | $0.82 | +164.5% |
4Y Historical EPS CAGR: 164.5%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.